ORKA

SEC source: 0000907654-26-000106 · form4.xml · derivative · entry 8

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,875

Underlying: Common Stock · 1,458 shares

Expires 2036-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

SEC source: 0000907654-26-000106 · form4.xml · derivative · entry 7

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,376

Underlying: Common Stock · 8,541 shares

Expires 2035-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

SEC source: 0000907654-26-000106 · form4.xml · nonDerivative · entry 6

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,219

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.76 to $82.91, inclusive.

SEC source: 0000907654-26-000106 · form4.xml · nonDerivative · entry 5

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,419

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.61 to $82.50, inclusive.

SEC source: 0000907654-26-000106 · form4.xml · nonDerivative · entry 4

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,377

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.56 to $81.53, inclusive.

SEC source: 0000907654-26-000106 · form4.xml · nonDerivative · entry 3

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,477

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.55 to $80.54, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

SEC source: 0000907654-26-000106 · form4.xml · nonDerivative · entry 2

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000106 · form4.xml · nonDerivative · entry 1

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000104 · form4.xml · derivative · entry 5

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,528,513

Underlying: Common Stock · 25,000 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

SEC source: 0000907654-26-000104 · form4.xml · nonDerivative · entry 4

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 923,128

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $84.81, inclusive.

SEC source: 0000907654-26-000104 · form4.xml · nonDerivative · entry 3

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 923,328

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.69, inclusive.

SEC source: 0000907654-26-000104 · form4.xml · nonDerivative · entry 2

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 931,882

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.75 to $83.73, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

SEC source: 0000907654-26-000104 · form4.xml · nonDerivative · entry 1

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 948,128

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000102 · form4.xml · nonDerivative · entry 1

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,219

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

SEC source: 0000907654-26-000100 · form4.xml · derivative · entry 6

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,996

Underlying: Common Stock · 10,000 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.

SEC source: 0000907654-26-000100 · form4.xml · nonDerivative · entry 5

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,995

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.05 to $95.75, inclusive.

SEC source: 0000907654-26-000100 · form4.xml · nonDerivative · entry 4

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,662

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.02 to $94.98, inclusive.

SEC source: 0000907654-26-000100 · form4.xml · nonDerivative · entry 3

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,263

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive.

SEC source: 0000907654-26-000100 · form4.xml · nonDerivative · entry 2

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,095

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.87 to $92.78, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

SEC source: 0000907654-26-000100 · form4.xml · nonDerivative · entry 1

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,995

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000098 · form4.xml · derivative · entry 9

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 164,992

Underlying: Common Stock · 3,500 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

SEC source: 0000907654-26-000098 · form4.xml · derivative · entry 8

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 193,563

Underlying: Common Stock · 3,500 shares

Expires 2034-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

SEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 7

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,771

F6 · kind: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

SEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 6

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,718

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.04 to $94.35, inclusive.

SEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 5

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,818

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.62 to $93.54, inclusive.

SEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 4

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,184

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.56 to $92.55, inclusive.

SEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 3

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,334

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.52 to $91.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

SEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 2

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,718

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000097 · form4.xml · nonDerivative · entry 7

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,752

F6 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

SEC source: 0000907654-26-000096 · form4.xml · nonDerivative · entry 1

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 923,128

F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

SEC source: 0000907654-26-000095 · form4.xml · nonDerivative · entry 1

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,995

F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

SEC source: 0000907654-26-000094 · form4.xml · nonDerivative · entry 1

Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 235,478

F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

SEC source: 0000907654-26-000097 · form4.xml · derivative · entry 9

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,333

Underlying: Common Stock · 1,459 shares

Expires 2036-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

SEC source: 0000907654-26-000097 · form4.xml · derivative · entry 8

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,917

Underlying: Common Stock · 8,000 shares

Expires 2035-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

SEC source: 0000907654-26-000097 · form4.xml · nonDerivative · entry 6

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,312

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.98 to $94.05, inclusive.

SEC source: 0000907654-26-000097 · form4.xml · nonDerivative · entry 5

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,512

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.775 to $93.40, inclusive.

SEC source: 0000907654-26-000097 · form4.xml · nonDerivative · entry 4

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,720

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.74 to $92.71, inclusive.

SEC source: 0000907654-26-000097 · form4.xml · nonDerivative · entry 3

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,771

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.71 to $91.50, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

SEC source: 0000907654-26-000097 · form4.xml · nonDerivative · entry 2

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000097 · form4.xml · nonDerivative · entry 1

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,312

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000088 · form4.xml · derivative · entry 4

Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,996

Underlying: Common Stock · 5,000 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

SEC source: 0000907654-26-000088 · form4.xml · nonDerivative · entry 3

Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 236,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.60 to $92.59, inclusive.

SEC source: 0000907654-26-000088 · form4.xml · nonDerivative · entry 2

Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 240,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.51 to $91.49, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

SEC source: 0000907654-26-000088 · form4.xml · nonDerivative · entry 1

Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 241,384

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000087 · form4.xml · derivative · entry 5

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,553,513

Underlying: Common Stock · 75,000 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

SEC source: 0000907654-26-000087 · form4.xml · nonDerivative · entry 4

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 925,580

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.31 to $92.59, inclusive.

SEC source: 0000907654-26-000087 · form4.xml · nonDerivative · entry 3

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 930,380

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.28 to $92.27, inclusive.

SEC source: 0000907654-26-000087 · form4.xml · nonDerivative · entry 2

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 993,976

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.27 to $91.26, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

SEC source: 0000907654-26-000087 · form4.xml · nonDerivative · entry 1

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,000,580

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.